Role of 5-aminosalicylic acid (5-ASA) in treatment of inflammatory bowel disease: a systematic review.
about
Tolerance of 4-aminosalicylic acid enemas in patients with inflammatory bowel disease and 5-aminosalicylic-induced acute pancreatitisExpression, purification, characterization and structure of Pseudomonas aeruginosa arylamine N-acetyltransferaseA randomized, double-blind trial of Lactobacillus GG versus placebo in addition to standard maintenance therapy for children with Crohn's disease.Don't Forget the Doctor: Gastroenterologists' Preferences on the Development of mHealth Tools for Inflammatory Bowel DiseaseReview article: diagnosis, monitoring and treatment of distal colitis.PRISMA--efficacy and safety of vedolizumab for inflammatory bowel diseases: a systematic review and meta-analysis of randomized controlled trials.Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trial.Review article: aminosalicylates in inflammatory bowel disease.Drug safety in the treatment of Crohn's disease.Drug bioactivation, covalent binding to target proteins and toxicity relevance.Effect of a probiotic beverage consumption (Enterococcus faecium CRL 183 and Bifidobacterium longum ATCC 15707) in rats with chemically induced colitis5-Aminosalicylates and renal function in inflammatory bowel disease: a systematic review.Treatment of inflammatory bowel disease: a review of medical therapy.Drug safety in Crohn's disease therapy.Usefulness of sulfasalazine for patients with refractory-ulcerative colits.Safety of 5-Aminosalicylic Acid Derivatives in Patients with Sensitivity to Acetylsalicylic Acid and Nonsteroidal Anti-inflammatory Drugs.Colon-specific prodrugs of 4-aminosalicylic acid for inflammatory bowel disease.Oxidative stress as a mechanism underlying sulfasalazine-induced toxicity.Mesalazine Modified-Release Tablet in the Treatment of Ulcerative Colitis in the Active Phase: A Chinese, Multicenter, Single-Blind, Randomized Controlled Study.Effects of Mesalamine Treatment on Gut Barrier Integrity After Burn Injury.Short-term effect and adverse events of adalimumab versus placebo in inducing remission for moderate-to-severe ulcerative colitis: a meta-analysis.Usefulness of salicylate and thiopurine coprescription in steroid-dependent ulcerative colitis and withdrawal strategies.Common misconceptions about 5-aminosalicylates and thiopurines in inflammatory bowel disease.Development and in vitro evaluation of mesalamine delayed release pellets and tableted reservoir-type pellets.Comparison of two different daily dosages (2.4 vs. 1.2 g) of oral mesalazine in maintenance of remission in ulcerative colitis patients: 1-year follow-up study.The case for using 5-aminosalicyclates in Crohn's disease: pro.Intestinal organoids containing poly(lactic-co-glycolic acid) nanoparticles for the treatment of inflammatory bowel diseases.Physician Perspectives on Unresolved Issues in the Management of Ulcerative Colitis: The UC Horizons Project.Efficacy of topical versus oral 5-aminosalicylate for treatment of 2,4,6-trinitrobenzene sulfonic acid-induced ulcerative colitis in rats.
P2860
Q28275376-BA2359AF-89D9-427B-835A-DC30CBC0F78CQ28493134-1EDFC1FB-9CF0-4A91-940B-2234FE6173DEQ34560319-D32C4F66-7C04-4E65-9A75-771259F7706FQ35056003-92D3B16B-EADE-4368-BAF2-FCBC76E454BEQ35144997-DBA793D3-5889-46B9-8C9E-E35D7D7474AFQ35530872-35833D0F-A36B-43B8-A0E2-C47494A49886Q35719665-79627113-E3E2-48B2-83D3-C8AF3E3325A6Q35880396-821117F9-E4B6-4A6E-A7A0-DC70EE0D7337Q36041692-D7AAC55B-46E3-497B-A315-C2F5F4137B74Q36061821-C5031838-C2F1-4CD7-902E-63C338AF3545Q36355121-ACC4856E-F17F-4E95-B799-36DF79C865A7Q36715466-F6A874B6-E0F7-4AD8-A979-006B5D9379B4Q37058862-A9E60AF6-1B70-4B12-ADA1-BA3706203AA0Q37073426-2EF879B7-071A-4E70-9A54-8F7375169AD9Q37236388-94148767-82F4-4FD7-AF1E-DA440CF27F13Q37635428-8B7B3BCB-549D-4CE7-88CD-078C3D90D4B1Q37682512-16A26F40-39E7-48D9-AA7B-5AA4EFA578E9Q37827164-2B17C0D9-5E1E-4739-8188-40738D412DF5Q38395688-EF27C6D9-5166-460E-9C4C-1417B66248ECQ41036330-CD9F6AE3-3F16-454C-8E34-356C69E8A4D9Q41807889-30EA3A72-60F0-4F33-A0D9-2639386E5C95Q42385055-49EF8339-4A3C-4BF9-8E24-4808E12AB602Q42877648-2529F553-ABAA-4F11-9E28-8246DADF52BCQ43279201-472C3406-7D96-49F1-B861-45338E211FF4Q46457587-5F244161-94D6-48D8-98F5-42D485EF1C67Q46500052-557BCF30-B5DD-4F27-A848-61B03F421EA3Q47262860-3454715E-36C4-4961-8869-8901BD7169E7Q50279083-8F4CA69D-F257-48A3-8B63-03CCFB52F869Q54224453-14ACEC34-E57D-4B3E-81D1-8553DFB96BDA
P2860
Role of 5-aminosalicylic acid (5-ASA) in treatment of inflammatory bowel disease: a systematic review.
description
2002 nî lūn-bûn
@nan
2002 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի մարտին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Role of 5-aminosalicylic acid ...... disease: a systematic review.
@ast
Role of 5-aminosalicylic acid ...... disease: a systematic review.
@en
Role of 5-aminosalicylic acid
@nl
type
label
Role of 5-aminosalicylic acid ...... disease: a systematic review.
@ast
Role of 5-aminosalicylic acid ...... disease: a systematic review.
@en
Role of 5-aminosalicylic acid
@nl
prefLabel
Role of 5-aminosalicylic acid ...... disease: a systematic review.
@ast
Role of 5-aminosalicylic acid ...... disease: a systematic review.
@en
Role of 5-aminosalicylic acid
@nl
P2093
P356
P1476
Role of 5-aminosalicylic acid ...... l disease: a systematic review
@en
P2093
Fernando Gomollón
José María Pajares
P2888
P304
P356
10.1023/A:1017987229718
P577
2002-03-01T00:00:00Z
P6179
1024478164